Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan
文献类型：期刊论文
| 作者 | Lei, Lei3; Chan, Han-Ching1; Lu, Tzu-Pin1; Cheng, Skye Hung-Chun2,4 |
| 刊名 | BREAST CANCER RESEARCH AND TREATMENT
 |
| 出版日期 | 2021-07-19 |
| 关键词 | Human epidermal growth factor receptor 2 Breast cancer Dutch criteria Taiwan |
| ISSN号 | 0167-6806 |
| DOI | 10.1007/s10549-021-06330-4 |
| 通讯作者 | Cheng, Skye Hung-Chun(skyecheng@gmail.com) |
| 英文摘要 | Purpose To assess the prognostic value of the Dutch criteria for patients with early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer from the Taiwan Cancer Registry Database. Patients and methods We included 8295 patients with early-stage node-negative breast cancer who underwent surgery during January 2008-December 2012. Patients were stratified into low- and high-risk groups based on the Dutch criteria. The Kaplan-Meier method and log-rank test were used to estimate the difference in breast cancer-specific survival (BCSS) and overall survival (OS) between groups. Multivariable analysis was used to evaluate the prognostic value of the Dutch criteria. Results Overall, the low-risk and high-risk groups comprised 5375 and 2920 patients, respectively. In the low- and high-risk groups, the 5-year BCSS rate was 99.6% and 98.2% (P < 0.0001) and the 5-year OS rate was 98.3% and 96.8% (P < 0.0001), respectively. The hazard ratio for BCSS was 4.18 (95% confidence interval [CI] 2.63-6.63, P < 0.0001), and the hazard ratio for OS was 1.94 (95% CI 1.48-2.55); both were significantly poorer in the high-risk group than in the low-risk group. In the low-risk group, the 5-year BCSS and OS of patients who did and did not receive adjuvant chemotherapy were similar (99.5% versus 99.6% [P = 0.927] and 98.8% and 98.1% [P = 0.0683], respectively). Conclusion The prognosis of low-risk patients as classified using the Dutch criteria is excellent with or without adjuvant chemotherapy. The benefit of multi-gene testing for chemotherapy decision-making might be minimal in these patients. |
| WOS关键词 | RECURRENCE SCORE ASSAY ; CHEMOTHERAPY ; SURVIVAL ; IMPACT |
| 资助项目 | Ministry of Science and Technology, Taipei, Taiwan[MOST 105-2314-B-368-001] ; Hammer Family Fund (2018-2020) ; Zhejiang Public Welfare Technology Research Program[LGJ20H160001] |
| WOS研究方向 | Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000674549800002 |
| 出版者 | SPRINGER |
| 资助机构 | Ministry of Science and Technology, Taipei, Taiwan ; Hammer Family Fund (2018-2020) ; Zhejiang Public Welfare Technology Research Program |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/123308]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Cheng, Skye Hung-Chun |
| 作者单位 | 1.Natl Taiwan Univ, Inst Epidemiol & Prevent Med, Dept Publ Hlth, Taipei, Taiwan 2.Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Koo Fdn, Taipei, Taiwan 3.Univ Chinese Acad Sci, Breast Oncol Dept, Canc Hosp, Beijing, Zhejiang, Peoples R China 4.Taitung Christian Hosp, Taitung Canc Ctr, Taitung, Taiwan |
| 推荐引用方式 GB/T 7714 | Lei, Lei,Chan, Han-Ching,Lu, Tzu-Pin,et al. Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan[J]. BREAST CANCER RESEARCH AND TREATMENT,2021. |
| APA | Lei, Lei,Chan, Han-Ching,Lu, Tzu-Pin,&Cheng, Skye Hung-Chun.(2021).Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan.BREAST CANCER RESEARCH AND TREATMENT. |
| MLA | Lei, Lei,et al."Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan".BREAST CANCER RESEARCH AND TREATMENT (2021). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。